TapImmune Announces Additional Funding

Bellevue WA, 25 November, 2009 – TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, within the last 60 days secured an additional $600,000 in equity funding, bringing the total for the last six months of 2009 to over $1,000,000. The recent investors acquired $.80…

Details

TapImmune Signs License Agreement With Crucell N.V.

BELLEVUE, Wash., Nov. 4, 2009 (GLOBE NEWSWIRE) — TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, has signed a license agreement with Crucell N.V. Under the license TapImmune may use the proprietary PER.C6(R) cells in its development programs. The PER.C6(R) cell line is ideally suited…

Details

TapImmune Provides Shareholder Update

Company Announces Appointment of New CFO and Interim Funding Bellevue WA, 1 October, 2009 – TapImmune Inc. (OTCBB: TPIV), a biotechnology company specializing in the development of immunotherapeutic vaccines for cancer and infectious diseases, provides this corporate update. In July 2009, the Company restructured the majority of its debt into equity with the aim of…

Details

TapImmune Announces Acquisition of Additional Technology

Company Completes Technology and IP Acquisition From The UBC Pursuant to an Option Agreement BELLEVUE, WA–(Marketwire – 08/05/09) – TapImmune Inc. (OTC.BB:TPIV – News), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announces the acquisition of three follow-on inventions and IP relating to its key TAP technology…

Details

TapImmune Announces Corporate Restructuring

Bellevue WA – TapImmune Inc. (OTCBB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, announces the appointment of Dr. Glynn Wilson as TapImmune’s new Executive Chairman as part of an overall corporate restructuring plan. Dr. Wilson succeeds Alan Lindsay whom TapImmune Inc. thanks for his service…

Details

TapImmune Issued U.S. Patent Relating To Methods For Enhancing An Immune Response

Patent Strengthens Company Intellectual Property Portfolio VANCOUVER, Canada, June 30, 2008 – TapImmune Inc., (OTCBB: TPIM) announced today the U.S. Patent and Trademark Office (USPTO) has issued U.S. patent No. 7,378,087, entitled “Method of Enhancing an Immune Response.” The patent claims relate to methods for enhancing the immune response to tumor cells by introducing the…

Details

TapImmune Announces Execution of Exclusive Option Agreement with The University of British Columbia

VANCOUVER, BC – June 9, 2008 — TapImmune Inc. (OTC BB: TPIM), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced that the company has executed an exclusive option agreement with The University of British Columbia (UBC) for three follow on technologies related to the original…

Details

Published Third Party, Independent Research Corroborates Promise of TAP Cancer Therapeutic as a Therapy for the Treatment of Cancer

VANCOUVER, BC–(MARKET WIRE)–Jun 2, 2008 — TapImmune Inc. (OTC BB:TPIM.OB – News), a biotechnology company specializing in the development of immunotherapeutics for cancer and vaccines for infectious diseases, today announced that an independent third party research article in the Journal of Investigative Dermatology has confirmed and corroborated that a TAP incorporated vaccine should be considered…

Details

TapImmune Provides Shareholder Update and Review

Company Announces Completion of Initial Sterility Testing VANCOUVER, BC–(MARKET WIRE)–Apr 21, 2008 — TapImmune Inc. (OTC BB:TPIM.OB – News) (Frankfurt:GX1A.F – News) announces completion of initial testing on our bench made vaccine at AppTech. The company now has the necessary data to proceed with clinical grade vaccine stock production. Going forward, our work and development…

Details

Tapimmune Receives Notice Of Allowance For U.S. Patent Relating To Methods For Enhancing An Immune Response

VANCOUVER, Canada, January 22, 2008 – TapImmune Inc., (OTCBB: TPIM; Germany: GX1A) announced today the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application No. 10/046,542, entitled “Method of Enhancing an Immune Response.” The patent application has allowed claims that relate to methods for enhancing the cytotoxic T-lymphocyte…

Details